1. ZHAW digitalcollection
  2. Life Sciences und Facility Management
  3. Publikationen
  4. Publikationen Life Sciences und Facility Management
Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-26763
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBommer, Claudine-
dc.contributor.authorWaller, Tobias-
dc.contributor.authorHilbe, Monika-
dc.contributor.authorWiedemeier, Daniel-
dc.contributor.authorMeyer, Nina-
dc.contributor.authorMathes, Stephanie-
dc.contributor.authorJung, Ronald-
dc.date.accessioned2023-02-06T10:00:56Z-
dc.date.available2023-02-06T10:00:56Z-
dc.date.issued2022-
dc.identifier.issn1432-6981de_CH
dc.identifier.issn1436-3771de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/26763-
dc.descriptionErworben im Rahmen der Schweizer Nationallizenzen (http://www.nationallizenzen.ch)de_CH
dc.description.abstractObjectives: This study’s aim was to investigate the safety and performance of a self-assembling peptide matrix (SAPM) P11-4 for the treatment of periodontal disease in a controlled pre-clinical study. Materials and methods: Acute buccal bony dehiscence defects (LxW: 5 × 3 mm) were surgically created on the distal root of four teeth on one mandible side of 7 beagle dogs followed by another identical surgery 8 weeks later on the contralateral side. SAPM P11-4 (with and without root conditioning with 24% EDTA (T1, T2)), Emdogain® (C) and a sham intervention (S) were randomly applied on the four defects at each time point. Four weeks after the second surgery and treatment, the animals were sacrificed, the mandibles measured by micro-computed tomography (µ-CT) and sections of the tissue were stained and evaluated histologically. Results: Clinically and histologically, no safety concerns or pathological issues due to the treatments were observed in any of the study groups at any time point. All groups showed overall similar results after 4 and 12 weeks of healing regarding new cementum, functionality of newly formed periodontal ligament and recovery of height and volume of the new alveolar bone and mineral density. Conclusion: A controlled clinical study in humans should be performed in a next step as no adverse effects or safety issues, which might affect clinical usage of the product, were observed. Clinical relevance: The synthetic SAPM P11-4 may offer an alternative to the animal-derived product Emdogain® in the future.de_CH
dc.language.isoende_CH
dc.publisherSpringerde_CH
dc.relation.ispartofClinical Oral Investigationsde_CH
dc.rightshttps://creativecommons.org/licenses/by/4.0/de_CH
dc.subjectDehiscence defectde_CH
dc.subjectDogde_CH
dc.subjectPeriodontal diseasede_CH
dc.subjectRegenerative scaffoldde_CH
dc.subjectSelf-assembling peptide P11-4de_CH
dc.subjectAlveolar bone lossde_CH
dc.subjectAnimalde_CH
dc.subjectBone regenerationde_CH
dc.subjectDental cementumde_CH
dc.subjectMandiblede_CH
dc.subjectTooth rootde_CH
dc.subjectX-ray microtomographyde_CH
dc.subjectGuided tissue regeneration, periodontalde_CH
dc.subjectOligopeptidede_CH
dc.subjectPeriodontal ligamentde_CH
dc.subject.ddc617: Chirurgiede_CH
dc.titleEfficacy and safety of P11-4 for the treatment of periodontal defects in dogsde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementLife Sciences und Facility Managementde_CH
zhaw.organisationalunitInstitut für Chemie und Biotechnologie (ICBT)de_CH
dc.identifier.doi10.1007/s00784-021-04297-6de_CH
dc.identifier.doi10.21256/zhaw-26763-
dc.identifier.pmid35006293de_CH
zhaw.funding.euNode_CH
zhaw.issue3de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end3166de_CH
zhaw.pages.start3151de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume26de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen Life Sciences und Facility Management

Files in This Item:
File Description SizeFormat 
2022_Bommer-etal_Efficacy-and-safety-P11-4-periodontal-defect-treatment-dogs.pdf2.85 MBAdobe PDFThumbnail
View/Open
Show simple item record
Bommer, C., Waller, T., Hilbe, M., Wiedemeier, D., Meyer, N., Mathes, S., & Jung, R. (2022). Efficacy and safety of P11-4 for the treatment of periodontal defects in dogs. Clinical Oral Investigations, 26(3), 3151–3166. https://doi.org/10.1007/s00784-021-04297-6
Bommer, C. et al. (2022) ‘Efficacy and safety of P11-4 for the treatment of periodontal defects in dogs’, Clinical Oral Investigations, 26(3), pp. 3151–3166. Available at: https://doi.org/10.1007/s00784-021-04297-6.
C. Bommer et al., “Efficacy and safety of P11-4 for the treatment of periodontal defects in dogs,” Clinical Oral Investigations, vol. 26, no. 3, pp. 3151–3166, 2022, doi: 10.1007/s00784-021-04297-6.
BOMMER, Claudine, Tobias WALLER, Monika HILBE, Daniel WIEDEMEIER, Nina MEYER, Stephanie MATHES und Ronald JUNG, 2022. Efficacy and safety of P11-4 for the treatment of periodontal defects in dogs. Clinical Oral Investigations. 2022. Bd. 26, Nr. 3, S. 3151–3166. DOI 10.1007/s00784-021-04297-6
Bommer, Claudine, Tobias Waller, Monika Hilbe, Daniel Wiedemeier, Nina Meyer, Stephanie Mathes, and Ronald Jung. 2022. “Efficacy and Safety of P11-4 for the Treatment of Periodontal Defects in Dogs.” Clinical Oral Investigations 26 (3): 3151–66. https://doi.org/10.1007/s00784-021-04297-6.
Bommer, Claudine, et al. “Efficacy and Safety of P11-4 for the Treatment of Periodontal Defects in Dogs.” Clinical Oral Investigations, vol. 26, no. 3, 2022, pp. 3151–66, https://doi.org/10.1007/s00784-021-04297-6.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.